Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 11,377 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohorting Clear all
Completed Phase 1 Interventional

BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

NCT02155088
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
BYL719, Gemcitabine, (nab)-paclitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 31, 2026, 6:05 PM EDT
Recruiting No phase listed Observational

CRPS-RISE Outcomes Registry

NCT07811362
View directory record Official record
Conditions
Complex Regional Pain Syndrome I (CRPS I)
Interventions
Not listed
Lead sponsor
Ambros Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 6:05 PM EDT
Completed No phase listed Observational

Advancing Telestroke Care: A Prospective Observational Study

NCT01226862
View directory record Official record
Conditions
Stroke
Interventions
Not listed
Lead sponsor
National Stroke Association, United States
Other
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 31, 2026, 6:05 PM EDT
Recruiting Phase 1 Interventional

E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

NCT04190862
View directory record Official record
Conditions
Anal Fistula
Interventions
E-CEL UVEC
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 31, 2026, 6:05 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

NCT04017962
View directory record Official record
Conditions
CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions
Letermovir Pill, blood draw
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 31, 2026, 6:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

NCT01610388
View directory record Official record
Conditions
Infections, Bacterial
Interventions
500mg IV GSK1322322/placebo, 1000mg oral GSK1322322/placebo, 1000mg IV GSK1322322/placebo, 1500mg oral GSK1322322/placebo dose, 1500mg IV GSK1322322/placebo, 2000mg IV GSK1322322J/placebo, 3000mg IV GSK1322322J/placebo, 1000mg IV GSK1322322J/placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 31, 2026, 6:05 PM EDT
Completed No phase listed Observational

Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment

NCT02396862
View directory record Official record
Conditions
Hemophilia A
Interventions
Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years and older · Male only
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 31, 2026, 6:05 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

NCT04599062
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Talimogene Laherparepvec, Radiotherapy
Drug · Radiation
Lead sponsor
John Rieth
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 31, 2026, 6:05 PM EDT
Recruiting Phase 2 Interventional

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

NCT06397703
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide, Degarelix or Relugolix, Stereotactic body radiation therapy/radiosurgery (SBRT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 31, 2026, 6:05 PM EDT
Enrolling by invitation No phase listed Observational

A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy

NCT05503927
View directory record Official record
Conditions
Pregnancy, Obesity, Overweight
Interventions
No Intervention
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
2,701 participants
Timeline
2020 – 2027
U.S. locations
2
States / cities
Ann Arbor, Michigan • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 31, 2026, 6:05 PM EDT
Suspended Phase 1 Interventional

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

NCT06968988
View directory record Official record
Conditions
Metastatic Soft-tissue Sarcoma
Interventions
Zanzalintinib, Ipilimumab, Nivolumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 31, 2026, 6:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders

NCT00911690
View directory record Official record
Conditions
Dementia, Alzheimers Disease
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
60 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 31, 2026, 6:05 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

NCT00838110
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
93
States / cities
Mobile, Alabama • Northport, Alabama • Little Rock, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 31, 2026, 6:05 PM EDT
Completed No phase listed Observational

Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis

NCT02165579
View directory record Official record
Conditions
Diabetes, Foot Ulcer, Osteomyelitis
Interventions
1 cohort, standard care, observational
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 31, 2026, 6:05 PM EDT
Active, not recruiting Phase 1 Interventional

QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations

NCT06715124
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
QTX3544, Cetuximab
Drug · Combination Product
Lead sponsor
Quanta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Denver, Colorado • New Haven, Connecticut • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 31, 2026, 6:05 PM EDT
Completed Not applicable Interventional

Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study

NCT05977881
View directory record Official record
Conditions
HIV Infections
Interventions
CHECKIT!
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 31, 2026, 6:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Liking Adaptation to Beverages With Varying Sweetness Levels After Prolonged Exposure

NCT04609657
View directory record Official record
Conditions
Sweetness Liking Adaptation
Interventions
Flavored carbonated soft drink (CSD)
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
25 Years to 55 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 31, 2026, 6:05 PM EDT
Not listed No phase listed Observational

Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)

NCT04654975
View directory record Official record
Conditions
Esophageal Neoplasms, Esophagectomy, Brain Metastases
Interventions
Esophagectomy for esophageal cancer
Procedure
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 31, 2026, 6:05 PM EDT
Not listed Phase 2 Interventional

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

NCT01095120
View directory record Official record
Conditions
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
Interventions
Tesetaxel
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 31, 2026, 6:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Inflammation, Diabetes, Ethnicity and Obesity Cohort

NCT03022682
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Pre Diabetes
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 31, 2026, 6:05 PM EDT
Completed Phase 1 Interventional Results available

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse

NCT01690624
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
BI 836858
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 31, 2026, 6:05 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

NCT04478279
View directory record Official record
Conditions
Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions
ST101, Temozolomide, Radiation
Drug · Radiation
Lead sponsor
Sapience Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 31, 2026, 6:05 PM EDT
Completed Phase 3 Interventional

Long-Term Follow-Up to the DEVO Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

NCT01891760
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Dermagraft, Profore
Device
Lead sponsor
Shire Regenerative Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Phoenix, Arizona • Fresno, California • Mather, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 31, 2026, 6:05 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection

NCT07536282
View directory record Official record
Conditions
Persistent HPV16 Infection
Interventions
NWRD09, Placebo
Biological
Lead sponsor
Newish Biotech (Wuxi) Co., Ltd.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 31, 2026, 6:05 PM EDT